CLINICAL ROLE -
Relapsed Hodgkin Lymphoma Combination Shows Promise
The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) found to be active and safe in relapsed/refractory classical Hodgkin lymphoma.
Read More